Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Biokinetics and dosimetry of 18F-PSMA-1007 in patients with prostate cancer

Hvittfeldt, Erland LU orcid ; Bjöersdorff, Mimmi LU orcid ; Brolin, Gustav LU ; Minarik, David LU ; Svegborn, Sigrid L. ; Oddstig, Jenny LU and Trägårdh, Elin LU (2022) In Clinical Physiology and Functional Imaging 42(6). p.443-452
Abstract

Purpose: Positron emission tomography-computed tomography (PET-CT) using prostate-specific membrane antigen (PSMA) ligands is a method for imaging prostate cancer. A recent tracer, 18F-PSMA-1007, offers advantages concerning production and biokinetics compared to the standard tracer (68Ga-PSMA-11). Until now, radiation dosimetry data for this ligand was limited to the material of three healthy volunteers. The purpose of this study is to study the biokinetics and dosimetry of 18F-PSMA-1007. Methods: Twelve patients with prostate cancer were injected with 4 MBq/kg 18F-PSMA-1007. Eight PET-CT scans with concomitant blood sampling were performed up to 330 min after injection. Urine was collected... (More)

Purpose: Positron emission tomography-computed tomography (PET-CT) using prostate-specific membrane antigen (PSMA) ligands is a method for imaging prostate cancer. A recent tracer, 18F-PSMA-1007, offers advantages concerning production and biokinetics compared to the standard tracer (68Ga-PSMA-11). Until now, radiation dosimetry data for this ligand was limited to the material of three healthy volunteers. The purpose of this study is to study the biokinetics and dosimetry of 18F-PSMA-1007. Methods: Twelve patients with prostate cancer were injected with 4 MBq/kg 18F-PSMA-1007. Eight PET-CT scans with concomitant blood sampling were performed up to 330 min after injection. Urine was collected until the following morning. Volumes of interest for radiation-sensitive organs and organs with high uptake of 18F-PSMA-1007 were drawn in the PET images. A biokinetic compartment model was developed using activity data from PET images and blood and urine samples. Time-activity curves and time-integrated activity coefficients for all delineated organs were calculated. The software IDAC-dose 2.1 was used to calculate the absorbed and effective doses. Results: High concentrations of activity were noted in the liver, kidneys, parts of the small intestine, spleen, salivary glands, and lacrimal glands. The elimination through urine was 8% of injected activity in 20 h. The highest absorbed doses coefficients were in the lacrimal glands, kidneys, salivary glands, liver, and spleen (98–66 µGy/MBq). The effective dose coefficient was 25 µSv/MBq. Conclusion: The effective dose of 18F-PSMA-1007 is 6.0–8.0 mSv for a typical patient weighing 80 kg injected with 3–4 MBq/kg.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biodistribution, dosimetry, prostate cancer, PSMA, PSMA-1007
in
Clinical Physiology and Functional Imaging
volume
42
issue
6
pages
10 pages
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85137526836
  • pmid:36039853
ISSN
1475-0961
DOI
10.1111/cpf.12785
language
English
LU publication?
yes
id
6492b81c-cd12-4453-b92e-9c85df0b907a
date added to LUP
2022-10-21 15:03:23
date last changed
2024-09-20 05:33:03
@article{6492b81c-cd12-4453-b92e-9c85df0b907a,
  abstract     = {{<p>Purpose: Positron emission tomography-computed tomography (PET-CT) using prostate-specific membrane antigen (PSMA) ligands is a method for imaging prostate cancer. A recent tracer, <sup>18</sup>F-PSMA-1007, offers advantages concerning production and biokinetics compared to the standard tracer (<sup>68</sup>Ga-PSMA-11). Until now, radiation dosimetry data for this ligand was limited to the material of three healthy volunteers. The purpose of this study is to study the biokinetics and dosimetry of <sup>18</sup>F-PSMA-1007. Methods: Twelve patients with prostate cancer were injected with 4 MBq/kg <sup>18</sup>F-PSMA-1007. Eight PET-CT scans with concomitant blood sampling were performed up to 330 min after injection. Urine was collected until the following morning. Volumes of interest for radiation-sensitive organs and organs with high uptake of <sup>18</sup>F-PSMA-1007 were drawn in the PET images. A biokinetic compartment model was developed using activity data from PET images and blood and urine samples. Time-activity curves and time-integrated activity coefficients for all delineated organs were calculated. The software IDAC-dose 2.1 was used to calculate the absorbed and effective doses. Results: High concentrations of activity were noted in the liver, kidneys, parts of the small intestine, spleen, salivary glands, and lacrimal glands. The elimination through urine was 8% of injected activity in 20 h. The highest absorbed doses coefficients were in the lacrimal glands, kidneys, salivary glands, liver, and spleen (98–66 µGy/MBq). The effective dose coefficient was 25 µSv/MBq. Conclusion: The effective dose of <sup>18</sup>F-PSMA-1007 is 6.0–8.0 mSv for a typical patient weighing 80 kg injected with 3–4 MBq/kg.</p>}},
  author       = {{Hvittfeldt, Erland and Bjöersdorff, Mimmi and Brolin, Gustav and Minarik, David and Svegborn, Sigrid L. and Oddstig, Jenny and Trägårdh, Elin}},
  issn         = {{1475-0961}},
  keywords     = {{biodistribution; dosimetry; prostate cancer; PSMA; PSMA-1007}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{443--452}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Clinical Physiology and Functional Imaging}},
  title        = {{Biokinetics and dosimetry of <sup>18</sup>F-PSMA-1007 in patients with prostate cancer}},
  url          = {{http://dx.doi.org/10.1111/cpf.12785}},
  doi          = {{10.1111/cpf.12785}},
  volume       = {{42}},
  year         = {{2022}},
}